EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of T-Cell Anaplastic Large Cell Lymphoma Relapsing after Autologous Stem Cell Transplant with Denileukin Difitox



Treatment of T-Cell Anaplastic Large Cell Lymphoma Relapsing after Autologous Stem Cell Transplant with Denileukin Difitox



Blood 100(11): Abstract No 4772, November 16



ALCL, T/null cell type is the second most common T-cell lymphoma and represents approximately 2% of all adult Non-Hodgkin's lymphoma. The neoplastic cells express CD30 (Ki-1) and either T-cell or no lineage specific antigens. ALCL often expresses CD25 (IL-2 receptor). While most cases of cutaneous ALCL are anaplastic lymphoma kinase (ALK) negative, the majority of systemic cases are positive for ALK. In general, the prognosis for systemic ALK negative ALCL in adults is poor and therapy is not well defined. Ontak is a targeted, cytotoxic fusion protein consisting of diphtheria toxin bound to human IL-2. We report two patients with primary systemic T cell ALCL (ALK negative, CD25 positive) treated with Ontak at relapse after ASCT to demonstrate its safety and lack of organ toxicity. Case 1: A 64 year-old man presented with stage I-A ALCL involving left cervical nodes. Based on normal LDH and PS 0, he had low age-adjusted IPI (aaIPI). CR was achieved with 3 cycles of CHOP and local RT. After 12 months, he relapsed in small bowel and mesenteric nodes. With 2 cycles of salvage DHAC (cytarabine, dexamethasone and carboplatin), he had no evidence of disease and underwent ASCT using cyclophosphamide (CPA), thiotepa and etoposide. He had recurrence in abdominal lymph nodes 2 months post-transplant. He received one cycle of Ontak (5 doses at 9 mcg/kg/dose every other day) and tolerated the infusion well without developing any hematologic or organ toxicity. No response was noted and the patient went on to receive multiple other agents but died of recurrence 11 months post-transplant. Case 2: A 53 year-old man presented with stage III-B ALCL involving cervical, mediastinal and paraaortic nodes and the spleen. Based on normal LDH and PS 1, the aaIPI was low intermediate . After 4 cycles of CHOP, splenomegaly persisted. He underwent splenectomy confirming residual disease. After one cycle of ICE (ifosfamide, carboplatin and etoposide), CT and PET scans demonstrated CR. He underwent ASCT using CPA, etoposide and TBI. He had biopsy-proven recurrence in the liver 3 months post-transplant after presenting with a ten-fold increase in hepatic transaminases and total bilirubin of 11.8 mg/dl. One cycle of Ontak (5 doses at 9 mcg/kg/dose every other day) was given. It was well tolerated and the liver function tests improved remarkably (bilirubin decreased to 1.5 mg/dl and transaminase to two-fold above the normal) after four doses. He next received cyclophosphamide while awaiting search results for an unrelated stem cell donor but died within 3 months from progressive disease before undergoing allogeneic transplant. A search of the literature revealed only one report of Ontak administration pre-ASCT and two reports of its use in peripheral T-cell lymphomas. This is the first report of its use in the post-ASCT setting. The results demonstrate that administration of Ontak in this setting did not produce any infusion-related toxicity or any hematologic or organ toxicity. It also demonstrates that Ontak produced an objective clinical response in a patient with markedly abnormal liver function, a situation where other cytotoxic drugs would be prohibitive. These data provide a rationale for incorporation of Ontak into an early aggressive treatment plan for relapsed ALK negative ALCL to further evaluate its efficacy.

(PDF 0-2 workdays service: $29.90)

Accession: 035980623

Download citation: RISBibTeXText



Related references

High Dose Therapy and Autologous Stem Cell Transplant Does Not Result in Long Term Disease Free Survival in Patients with Recurrent Chemotherapy Sensitive Anaplastic Large Cell Lymphoma That Is Anaplastic Lymphoma Kinase Negative. Blood 100(11): Abstract No 2537, November 16, 2002

ALK-negative anaplastic lymphoma after autologous stem cell transplant for relapsed diffuse large B-cell lymphoma. Leukemia Research 35(6): E59-E60, 2011

Treatment of refractory peripheral T-cell lymphoma with denileukin difitox. Blood 98(11 Part 2): 250b, November 16, 2001

Relapse as peripheral T-cell lymphoma after autologous hemopoetic stem cell transplantation of secondary anaplastic large cell lymphoma. Blood 98(11 Part 2): 372b, November 16, 2001

Autologous stem cell transplantation for T-and null-cell types CD-30 positive anaplastic large cell lymphoma Preliminary analysis of 65 cases reported to the EBMT. Blood 90(10 SUPPL 1 PART 1): 232A, Nov 15, 1997

Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. Leukemia & Lymphoma 24(3-4): 369-377, 1997

Autologous graft-versus-host disease after denileukin diftitox and autologous stem cell transplantation for refractory T-cell lymphoma. Leukemia & Lymphoma 50(1): 124-126, 2009

Crizotinib for anaplastic large-cell lymphoma relapsed after autologous stem cell transplantation: a case report. Zhonghua Zhong Liu Za Zhi 38(6): 479-480, 2016

Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematologica 133(4): 347-353, 2015

Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation. European Journal of Haematology 74(3): 259-262, 2005

CD30-positive anaplastic large cell lymphoma of bone treated with autologous peripheral blood stem cell transplantation. Japanese Journal of Clinical Hematology 40(12): 1252-1257, 2000

Autologous peripheral stem-cell transplantation after intensive chemotherapy in a case of CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Journal of International Medical Research 29(5): 425-431, 2001

High-dose chemotherapy with autologous stem cell transplantation in a patient with a CD30+ anaplastic large cell lymphoma of the skin. British Journal of Dermatology 134(4): 811-813, 1996

Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. Leukemia & Lymphoma 54(5): 973-978, 2013

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. Journal of Clinical Oncology 29(10): 1342-1348, 2011